Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study

Journal of Clinical Oncology

Volumn 33, Issue 35, 2015, Pages 4176-4187

  André, Thierry ^a,b,c   De Gramont, Armand ^f,i   Vernerey, Dewi ^g   Chibaudel, Benoist ^c,f   Bonnetain, Franck ^g   Tijeras Raballand, Annemilaï ^c,f   Scriva, Aurelie ^f   Hickish, Tamas ^j   Tabernero, Josep ^k,l   Van Laethem, Jean Luc ^m   Banzi, Maria ⁿ   Maartense, Eduard ^o   Shmueli, Einat ^p   Carlsson, Goran U ^q   Scheithauer, Werner ^r   Papamichael, Demetris ^s   Möehler, Marcus ^t   Landolfi, Stefania ^k   Demetter, Pieter ^m   Colote, Soudhir ^c   Tournigand, Christophe ^h   Louvet, Christophe ^d   Duval, Alex ^e   Fléjou, Jean François ^a,b   De Gramont, Aimery ^c,f   more..

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c GERCOR Innovative Research Consortium   (France)

^d INSTITUT MUTUALISTE MONTSOURIS   (France)

^e INSERM   (France)

^f Hopital Franco britannique   (France)

^g HÔPITAL SAINT JACQUES   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j BOURNEMOUTH UNIVERSITY   (United Kingdom)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l TTD Group   (Spain)

^m ERASME HOSPITAL   (Belgium)

ⁿ S MARIA NUOVA HOSPITAL   (Italy)

^o REINIER DE GRAAF HOSPITAL   (Netherlands)

^p SHEBA MEDICAL CENTER   (Israel)

^q SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^r MEDICAL UNIVERSITY OF VIENNA   (Austria)

^s Bank of Cyprus Group Oncology Centre   (Cyprus)

^t JOHANNES GUTENBERG UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUOROURACIL; FOLINIC ACID; MISMATCH REPAIR PROTEIN PMS2; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; GLUTAMIC ACID; PLATINUM COMPLEX; VALINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; ELECTROCORTICOGRAPHY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TRANSLATIONAL RESEARCH; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLONIC NEOPLASMS; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; ODDS RATIO; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GLUTAMIC ACID; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ODDS RATIO; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT OUTCOME; VALINE;

EID: 84957568046     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.4238     Document Type: Article

References (32)

1. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
2. Andre T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
3. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007
4. Yothers G, O'Connell MJ, Allegra CJ, et al: Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29:3768-3774, 2011
5. Haller DG, Tabernero J, Maroun J, et al: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465-1471, 2011
6. Benson AB, III, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419, 2004
7. Labianca R, Nordlinger B, Beretta GD, et al: Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:64-72, 2013 (suppl 6)
8. Tournigand C, Andre T, Bonnetain F, et al: Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 30:3353-3360, 2012
9. Van Cutsem E, Cervantes A, Nordlinger B, et al: Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnostic, treatment and followup. Ann Oncol 25:1-9, 2015 (suppl 3)
10. National Cancer Comprehensive Network (NCCN): NCCN clinical practice guidelines in oncology. NCCN Guidelines, version 2.2015. http://www.nccn.org.
11. Hutchins G, Southward K, Handley K, et al: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261-1270, 2011
12. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
13. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226, 2010
14. Sargent DJ, Shi Q, Yothers G, et al: Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. J Clin Oncol 32:214s, 2014 (suppl; abstr 3507)
15. Sinicrope FA, Shi Q, Smyrk TC, et al: Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 148:88-99, 2015
16. Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 21:772-780, 2010
17. Tougeron D, Sickersen G, Lecomte T, et al: Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study. J Clin Oncol 32:215s, 2014 (suppl; abstr 3508).
18. Zaanan A, Fléjou JF, Emile JF, et al: Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res 17:7470-7478, 2011
19. Gavin PG, Colangelo LH, Fumagalli D, et al: Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18:6531-6541, 2012
20. Gavin PG, Paik S, Yothers G, et al: Colon cancer mutation: Prognosis/prediction-response. Clin Cancer Res 19:1301, 2013
21. Suraweera N, Duval A, Reperant M, et al: Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123:1804-1811, 2002
22. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
23. Haller FE, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
24. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al: The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 21:2396-2402, 2010
25. Tran B, Kopetz S, Tie J, et al: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:4623-4632, 2011
26. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466-474, 2010
27. Sinicrope FA, Mahoney MR, Smyrk TC, et al: Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 31:3664-3672, 2013
28. Ogino S, Shima K, Meyerhardt JA, et al: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res 18:890-900, 2012
29. Taieb J, Tabernero J, Mini E, et al: Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): An open-label, randomized phase 3 trial. Lancet Oncol 15:862-873, 2014
30. Venderbosch S, Nagtegaal ID, Maughan TS, et al: Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 20:5322-5330, 2014
31. Sinicrope FA, Foster NR, Thibodeau SN, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863-875, 2011
32. Renfro LA, Allegra CJ, Andre T, et al: Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin. J Clin Oncol 33:198s, 2015 (suppl; abstr 3593)